Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Eur J Nutr ; 58(6): 2425-2437, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30062492

RESUMEN

AIM: In the present study, we evaluated the therapeutic potentiality of S-allylcysteine (SAC) in streptozotocin (STZ)-nicotinamide (NAD)-induced diabetic nephropathy (DN) in experimental rats. METHODS: SAC was orally administered for 45 days to rats with STZ-NAD-induced DN; a metformin-treated group was included for comparison. Effect of SAC on body weight, organ weight, blood glucose, levels of insulin, glycated haemoglobin, and renal biochemical markers was determined. Body composition by total body electrical conductivity (TOBEC) and dual-X ray absorptiometry (DXA), kidney antioxidant analysis, real-time polymerase chain reaction, and western blot analysis of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), nuclear factor kappa B (NF-κB), interleukin (IL)-6, and tumor necrosis factor (TNF)-α; histopathological and scanning electron microscope (SEM) analysis of the kidneys were performed in both control and experimental rats. RESULTS: SAC treatment showed significantly decreased levels of blood glucose, glycated haemoglobin, creatinine, albumin, AST, ALT, creatinine kinase, lactate dehydrogenase, and expressions of NF-κB, IL-6, and TNF-α compared with DN control rats. Furthermore, SAC administration to DN rats significantly improved body composition and antioxidant defense mechanism which was confirmed by the upregulation of mRNA and protein expressions of antioxidant genes. CONCLUSIONS: Thus, SAC showed adequate therapeutic effect against DN by downregulation of inflammatory factors and attenuation of oxidative stress. Histological and SEM observations also indicated that SAC treatment notably reverses renal damage and protects the kidneys from hyperglycemia-mediated oxidative damage.


Asunto(s)
Cisteína/análogos & derivados , Diabetes Mellitus Experimental/complicaciones , Nefropatías Diabéticas/tratamiento farmacológico , Inflamación/prevención & control , Estrés Oxidativo/efectos de los fármacos , Animales , Antineoplásicos/farmacología , Antioxidantes/farmacología , Cisteína/farmacología , Nefropatías Diabéticas/etiología , Modelos Animales de Enfermedad , Masculino , Niacinamida , Ratas , Ratas Wistar , Estreptozocina
2.
Mol Cell Biochem ; 442(1-2): 143-154, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-28993954

RESUMEN

The present study evaluated the effects of asiatic acid (AA), a pentacyclic triterpenoid from Centella asiatica on lipid metabolism parameters in a rat model of obesity induced using a high fat diet (HFD) for 42 days. AA (20 mg/kg body weight [BW]) was administered orally once daily for 42 days, and an orlistat-treated group of rats (10 mg/kg BW) was included for comparison. Changes in BW, blood glucose levels, insulin resistance and leptin, adiponectin, amylase, and lipase levels in the blood; lipid profiles of plasma; liver antioxidants levels; and acetyl CoA carboxylase(ACC), uncoupling protein-2 (UCP2), and carnitine palmitoyltransferase-1 (CPT1) mRNA expression were observed in the experimental rats. Our results revealed that AA (20 mg/kg BW), similar to orlistat, reduced the increase in BW; increased bone mineral contents and bone mineral densities; reduced blood glucose levels, insulin resistance, leptin, plasma lipid levels; increased adiponectin, amylase, lipase levels in the blood; showed antioxidant activity; and altered mRNA expression of lipid metabolism-related genes, including ACC, UCP 2, and CPT 1, in the HFD-fed rats. From these results, we concluded that AA possesses significant anti-obesity potential through the suppression of BW gain, lipid lowering action, development of insulin and leptin sensitivity, antioxidant activity, and increased mRNA expression of lipid metabolism-related genes.


Asunto(s)
Acetiltransferasas/metabolismo , Carnitina O-Palmitoiltransferasa/metabolismo , Grasas de la Dieta/efectos adversos , Obesidad/metabolismo , Triterpenos Pentacíclicos/farmacología , Proteína Desacopladora 2/metabolismo , Animales , Grasas de la Dieta/farmacología , Metabolismo de los Lípidos/efectos de los fármacos , Masculino , Obesidad/inducido químicamente , Obesidad/patología , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley
3.
J Sci Food Agric ; 95(15): 3177-82, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25530163

RESUMEN

BACKGROUND: Diabetes is often connected with significant morbidity, mortality and also has a pivotal role in the development of cardiovascular diseases. Diet intervention, particularly naturaceutical antioxidants have anti-diabetic potential and avert oxidative damage linked with diabetic pathogenesis. The present study investigated the effects of diosgenin, a saponin from fenugreek, on the changes in lipid profile in plasma, liver, heart and brain in high-fat diet-streptozotocin (HFD-STZ)-induced diabetic rats. Diosgenin was administered to HFD-STZ induced diabetic rats by orally at 60 mg kg(-1) body weight for 30 days to assess its effects on body weight gain, glucose, insulin, insulin resistance and cholesterol, triglycerides, free fatty acids and phospholipids in plasma, liver, heart and brain. RESULTS: The levels of body weight, glucose, insulin, insulin resistance, cholesterol, triglycerides, free fatty acids, phospholipids, VLDL-C and LDL-C were increased significantly (P < 0.05) whereas HDL-C level decreased in the HFD/STZ diabetic rats. Administration of diosgenin to HFD-STZ diabetic rats caused a decrease in body weight gain, blood glucose, insulin, insulin resistance and also it modulated lipid profile in plasma and tissues. CONCLUSION: The traditional plant fenugreek and its constituents mediate its anti-diabetic potential through mitigating hyperglycaemic status, altering insulin resistance by alleviating metabolic dysregulation of lipid profile in both plasma and tissues.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Diosgenina/uso terapéutico , Dislipidemias/tratamiento farmacológico , Hiperglucemia/tratamiento farmacológico , Metabolismo de los Lípidos/efectos de los fármacos , Fitoterapia , Trigonella/química , Animales , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Glucemia/metabolismo , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/etiología , Dieta Alta en Grasa , Grasas de la Dieta/efectos adversos , Diosgenina/farmacología , Dislipidemias/sangre , Hiperglucemia/sangre , Hipoglucemiantes/farmacología , Hipoglucemiantes/uso terapéutico , Insulina/sangre , Resistencia a la Insulina , Lípidos/sangre , Masculino , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Ratas Wistar , Aumento de Peso/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA